Zobrazeno 1 - 10
of 394
pro vyhledávání: '"K. Clifton"'
Autor:
Mara Hofherr, Jennifer Hedgecorth, Foluso O. Ademuyiwa, Lindsay L. Peterson, Nusayba A. Bagegni, Rama Suresh, Ashley Frith, Ron Bose, Katherine Weilbaecher, Cynthia Ma, Andrew A. Davis, Katherine K. Clifton
Publikováno v:
Cancer Research. 83:P3-06
Background: KEYNOTE-522 was a randomized, double-blind, placebo-controlled phase 3 trial which resulted in the FDA approval of pembrolizumab with neoadjuvant chemotherapy for patients (pts) with newly diagnosed, high-risk, early-stage triple negative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03f3aee1684b824be546a3580854b791
https://doi.org/10.1158/1538-7445.sabcs22-p3-06-06
https://doi.org/10.1158/1538-7445.sabcs22-p3-06-06
Autor:
Nusayba A. Bagegni, Isabella Grigsby, Leslie Nehring, Jingqin Luo, Jennifer Powers Carson, David W. Gibson, Meghan Horvath, Katherine K. Clifton, Foluso O. Ademuyiwa, Rama Suresh, Ashley Frith, Andrew A. Davis, Lindsay L. Peterson, Ron Bose, Amy Williams, Mattias Bergqvist, Cynthia Ma
Publikováno v:
Cancer Research. 83:OT3-11
Background: CDK 4/6i have altered the therapeutic landscape of HR+, HER2- MBC, improving progression free and overall survival (PFS and OS) compared to endocrine therapy (ET) alone. Despite durable responses to CDK 4/6i in a large majority of patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::63a87133567d701ddd8ff3a693c4164d
https://doi.org/10.1158/1538-7445.sabcs22-ot3-11-01
https://doi.org/10.1158/1538-7445.sabcs22-ot3-11-01
Autor:
Katherine K. Clifton, Shana N. Thomas, Jingqin Luo, Jing Xi, Nusayba A. Bagegni, Foluso O. Ademuyiwa, Rama Suresh, Ashley Frith, Andrew A. Davis, Ron Bose, Katherine Weilbaecher, Whitney L. Hensing, Timothy Pluard, Massimo Cristofanilli, Hyo S. Han, Adam M. Brufsky, Kevin Kalinsky, Shom Goel, Seth A. Wander, Lindsay L. Peterson, Cynthia Ma
Publikováno v:
Cancer Research. 83:PD13-09
Background: CDK4/6 inhibitors (CDK4/6i) paired with endocrine therapy (ET) are considered first-line (1L) therapy for patients (pts) with HR+ HER2- advanced breast cancer (aBC). A minority of pts will demonstrate primary resistance to CDK4/6i, as cha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc74005a8ddece22f16b5410d530c3b0
https://doi.org/10.1158/1538-7445.sabcs22-pd13-09
https://doi.org/10.1158/1538-7445.sabcs22-pd13-09
Autor:
Andrew A. Davis, Leonel Hernandez-Aya, Jingqin Luo, Mateusz Opyrchal, Foluso O. Ademuyiwa, Nusayba A. Bagegni, Katherine K. Clifton, Jill Anderson, Trish Hammerschmidt, Leslie Nehring, David DeNardo, Mark Watson, Rebecca Aft, Cynthia Ma, Katherine Weilbaecher
Publikováno v:
Cancer Research. 83:P3-06
Background: Neoadjuvant immune checkpoint inhibition (ICI) in combination with chemotherapy is approved for patients with high-risk, early-stage triple-negative breast cancer (TNBC) based on improved outcomes in the KEYNOTE-522 trial. However, some p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62ee39f9967d655e9eda0cfed9531ebd
https://doi.org/10.1158/1538-7445.sabcs22-p3-06-07
https://doi.org/10.1158/1538-7445.sabcs22-p3-06-07
Autor:
Whitney L. Hensing, Joanne Xiu, W. Michael Korn, Stephanie L. Graff, Irene Kang, Evanthia T. Roussos Torres, Arielle L. Heeke, Andrew A. Davis, Nusayba A. Bagegni, Katherine K. Clifton, Ron Bose, Cynthia Ma, Foluso O. Ademuyiwa
Publikováno v:
Cancer Research. 83:P3-05
Introduction: Estrogen receptor (ER) loss occurs in about 20% of recurrent breast cancers (BC) and is associated with unresponsiveness to endocrine therapy (ET) and poor prognosis. Prior studies evaluating ER-loss included predominately patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5bcb7bc3af3f89462dd933887a3c847
https://doi.org/10.1158/1538-7445.sabcs22-p3-05-08
https://doi.org/10.1158/1538-7445.sabcs22-p3-05-08
Publikováno v:
Breast Cancer: Targets and Therapy. 14:113-123
Triple-negative breast cancer (TNBC) is a biologically aggressive yet heterogeneous disease that disproportionately affects younger women and women of color compared to other breast cancer subtypes. The paucity of effective targeted therapies and the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af115a5d59cf125e54f4720d3b82c05d
https://doi.org/10.2147/bctt.s293597
https://doi.org/10.2147/bctt.s293597
Autor:
Lorenzo Gerratana, Rossana Roncato, Mattia Sturlese, Andrew A. Davis, Marko Velimirovic, Carolina REDUZZI, Katherine K. Clifton, Whitney L. Hensing, Ami N. Shah, Charles S. Dai, Paolo D’Amico, Arielle J. Medford, Alessandra Franzoni, Linda Cucciniello, Firas Wehbe, Seth A. Wander, Barbara Belletti, William Gradishar, Amir Behdad, Giuseppe Damante, Cynthia Ma, Fabio Puglisi, Aditya Bardia, Massimo Cristofanilli
Publikováno v:
Cancer Research. 83:PD10-01
Background: ESR1 hotspot mutations (HS) (i.e. 380, 536, 537, and 538) are important drivers of resistance to aromatase inhibitors, but the differential impact of genomic variants (HS vs non-HS) on response to endocrine therapies (ET) under clinical d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2654d278eb73c9b4153d1d7076b87c70
https://doi.org/10.1158/1538-7445.sabcs22-pd10-01
https://doi.org/10.1158/1538-7445.sabcs22-pd10-01
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jennifer L. O’Brien, Jennifer J. Lister, Bernadette A. Fausto, Gregory K. Clifton, Jerri D. Edwards
Publikováno v:
Frontiers in Aging Neuroscience, Vol 9 (2017)
Auditory cognitive training (ACT) improves attention in older adults; however, the underlying neurophysiological mechanisms are still unknown. The present study examined the effects of ACT on the P3b event-related potential reflecting attention alloc
Externí odkaz:
https://doaj.org/article/0f391f0a0e30484e8fb180753e275832
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.